There was a court case last year in the states defending a patent in the cannabis medicine market. Won by the patent holder.
The FDA is removing from market and fining companies that place product on the market claiming medical use for a particular use, without any proof to back the claim. Now remember part of the Patent, will be the product composition. The FDA test product, and when they find that its composition is not the same as the packaging suggests, or it contains pestisides etc, it pulls the product, and palces a demand on the company to defend any claims it makes about the product. it then fines non compliant producers.
Having IP, and clinical testing, allows an easy way to defend the product composition, and provides dosing and evidence the product works.
Remember there is only one FDA registered CBD product at this time. This is being investigated and rethought at the moment. The problem being that the DEA still has cannabis and its products as sched 1 illegal drugs. Some states have legalised it, but federally, its still illegal.
IHL Price at posting:
5.2¢ Sentiment: Buy Disclosure: Held
